These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 9290623

  • 41. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients.
    Schober T, Framke T, Kreipe H, Schulz TF, Großhennig A, Hussein K, Baumann U, Pape L, Schubert S, Wingen AM, Jack T, Koch A, Klein C, Maecker-Kolhoff B.
    Transplantation; 2013 Jan 15; 95(1):240-6. PubMed ID: 23222898
    [Abstract] [Full Text] [Related]

  • 42. Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR.
    Michelson P, Watkins B, Webber SA, Wadowsky R, Michaels MG.
    Pediatr Transplant; 2008 Jun 15; 12(4):464-8. PubMed ID: 18466434
    [Abstract] [Full Text] [Related]

  • 43. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E, Shenton BK, Green K, Jackson G, Gould FK, Yap C, Talbot D.
    Transpl Infect Dis; 2004 Dec 15; 6(4):156-64. PubMed ID: 15762933
    [Abstract] [Full Text] [Related]

  • 44. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center.
    Angel LF, Cai TH, Sako EY, Levine SM.
    Ann Transplant; 2000 Dec 15; 5(3):26-30. PubMed ID: 11147026
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ, Perrine SP, Faller DV.
    Transpl Infect Dis; 2001 Sep 15; 3(3):177-85. PubMed ID: 11493400
    [Abstract] [Full Text] [Related]

  • 47. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease.
    Randhawa PS, Jaffe R, Demetris AJ, Nalesnik M, Starzl TE, Chen YY, Weiss LM.
    N Engl J Med; 1992 Dec 10; 327(24):1710-4. PubMed ID: 1331789
    [Abstract] [Full Text] [Related]

  • 48. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T, Delis S, Kato T, Nishida S, Mittal NK, Madariaga J, Levi D, Nery JR, Cirocco RE, Gelman B, Ruiz P, Tzakis AG.
    Transplantation; 2002 Oct 15; 74(7):1000-6. PubMed ID: 12394845
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, Hoyer P, Koepf S, Kraemer U, Laube GF, Müller-Wiefel DE, Netz H, Pohl M, Toenshoff B, Wagner HJ, Wallot M, Welte K, Melter M, Offner G, Klein C.
    J Clin Oncol; 2007 Nov 01; 25(31):4902-8. PubMed ID: 17971586
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.
    Sen A, Enriquez J, Rao M, Glass M, Balachandran Y, Syed S, Twist CJ, Weinberg K, Boyd SD, Bernstein D, Trickey AW, Gratzinger D, Tan B, Lapasaran MG, Robien MA, Brown M, Armstrong B, Desai D, Mazariegos G, Chin C, Fishbein TM, Venick RS, Tekin A, Zimmermann H, Trappe RU, Anagnostopoulos I, Esquivel CO, Martinez OM, Krams SM.
    Front Immunol; 2022 Nov 01; 13():994552. PubMed ID: 36304469
    [Abstract] [Full Text] [Related]

  • 55. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, Balistreri WF, Hornung RW.
    Transplantation; 2003 Apr 15; 75(7):987-93. PubMed ID: 12698085
    [Abstract] [Full Text] [Related]

  • 56. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep 15; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease.
    Wilsdorf N, Eiz-Vesper B, Henke-Gendo C, Diestelhorst J, Oschlies I, Hussein K, Pape L, Baumann U, Tönshoff B, Pohl M, Höcker B, Wingen AM, Klapper W, Kreipe H, Schulz TF, Klein C, Maecker-Kolhoff B.
    Transplantation; 2013 Jan 15; 95(1):247-55. PubMed ID: 23222899
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients.
    Morton LM, Landgren O, Chatterjee N, Castenson D, Parsons R, Hoover RN, Engels EA.
    Blood; 2007 Dec 15; 110(13):4599-605. PubMed ID: 17855632
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.